Plasma cell myeloma, characterized by clonally aberrant plasma cells that produce abnormal monoclonal Igs, is the most common indication for autologous hematopoietic progenitor cell transplantation (AHPCT) in North America. We observed appearance of new monoclonal gammopathies different from the original protein in the post-AHPCT setting and termed this condition secondary MGUS (monoclonal gammopathy of undetermined significance). Hence, we performed a retrospective, single institution review of serum protein electrophoresis/ immunofixation electrophoresis data in 92 AHPCT recipients from the period 2000-2009. In all, 22 of 92 patients (24%) undergoing AHPCT met criteria for secondary MGUS. Contrary to previous studies, often referred to as abnormal protein banding, we did not observe this condition as a favorable prognostic indicator in affected patients when compared with the control group (P0.686). However, we did note that a subgroup of the study cohort who developed secondary MGUS after a prolonged latency (10 months) had an improved median OS compared with the remainder of the study cohort (75 months vs 41 months, P0.005). As there have been significant advancements in understanding the pathobiology and clinical significance of MGUS, we believe that secondary MGUS merits dedication of resources for investigation to determine its true clinical relevance, prognostic value and pathophysiology.
- autologous hematopoietic progenitor cell transplant
- monoclonal gammopathy of undetermined significance
- plasma cell myeloma
ASJC Scopus subject areas